Search

Your search keyword '"Vojdanian, Mahdi"' showing total 16 results

Search Constraints

Start Over You searched for: Author "Vojdanian, Mahdi" Remove constraint Author: "Vojdanian, Mahdi" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
16 results on '"Vojdanian, Mahdi"'

Search Results

2. Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

4. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

5. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

7. Association of Killer Cell Immunoglobulin-like Receptor (KIR) Genes and their HLA Ligands with Susceptibility to Takayasu Arteritis in the Iranian Population

8. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

10. Additional file 1 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

11. Additional file 3 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

12. Additional file 2 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

13. Additional file 4 of Efficacy and safety of the biosimilar denosumab candidate (Arylia) compared to the reference product (Prolia®) in postmenopausal osteoporosis: a phase III, randomized, two-armed, double-blind, parallel, active-controlled, and noninferiority clinical trial

15. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

16. Authors and affiliations.

Catalog

Books, media, physical & digital resources